Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

Company Overview

Zentalis Pharmaceuticals (NASDAQ: ZNTL) is a clinical‐stage oncology company dedicated to the discovery and development of small molecule therapeutics designed to target key drivers of cancer growth and resistance. Since its founding in 2017, the company has built a robust pipeline grounded in precision science, with a focus on cell cycle and DNA damage response pathways. By leveraging proprietary chemistry technologies and structure-based drug design, Zentalis aims to deliver novel candidates that address unmet needs in solid tumors and hematologic malignancies.

The company’s lead asset, ZN‐C3, is a potent and selective WEE1 kinase inhibitor in Phase 2 development for patients with platinum‐resistant ovarian and other advanced solid tumors. ZN‐D5, a highly selective PLK1 inhibitor, is being evaluated for safety and efficacy both as a monotherapy and in combination with established chemotherapies. In addition to these clinical programs, Zentalis has a preclinical portfolio that includes inhibitors of ATR, CHK1, and other DNA damage repair targets, with the goal of creating rational combination regimens to enhance anti‐tumor activity and overcome resistance mechanisms.

Headquartered in New York City, Zentalis maintains research facilities in both the United States and Europe to support its global development strategy. The company collaborates with leading academic institutions and cancer centers to conduct early-stage trials and accelerate patient access to investigational therapies. Zentalis has also entered strategic partnerships with pharmaceutical companies to expand clinical development, access novel technologies, and prepare for potential commercialization of its most advanced programs.

Zentalis is led by a management team with extensive experience in oncology drug development, manufacturing, and regulatory affairs. Its executive leadership includes members who have played key roles in bringing multiple oncology products from discovery through approval. The company’s board of directors and scientific advisory board comprise seasoned experts in cancer biology, translational research, and clinical strategy, underscoring Zentalis’s commitment to advancing innovative therapies for patients with high‐unmet‐need cancers.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $1.16 to $1.63
• 52-Week Range: $1.01 to $5.44
• Volume: 623,162 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $95.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.37
• Consensus Rating: Moderate Buy

Zentalis Pharmaceuticals Stock Analysis - MarketRank™

Zentalis Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 592nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zentalis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zentalis Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zentalis Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zentalis Pharmaceuticals has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.61% of the float of Zentalis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zentalis Pharmaceuticals has recently increased by 31.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zentalis Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Zentalis Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.61% of the float of Zentalis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zentalis Pharmaceuticals has recently increased by 31.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.82

News Sentiment

Zentalis Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zentalis Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ZNTL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Zentalis Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Zentalis Pharmaceuticals is held by insiders.

ZNTL Stock Analysis - Frequently Asked Questions

How have ZNTL shares performed this year?

Zentalis Pharmaceuticals' stock was trading at $3.03 at the beginning of 2025. Since then, ZNTL shares have decreased by 56.1% and is now trading at $1.33.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released its earnings results on Wednesday, May, 14th. The company reported ($0.67) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.67).

When did Zentalis Pharmaceuticals IPO?

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering (IPO) on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Who are Zentalis Pharmaceuticals' major shareholders?

Top institutional investors of Zentalis Pharmaceuticals include Wealth Enhancement Advisory Services LLC (0.24%). Insiders that own company stock include Matrix Capital Management Comp, Cam Gallagher, Melissa B Epperly, Diana Hausman, Scott Dunseth Myers, Kimberly Blackwell, Mark Lackner, Vincent Vultaggio, Jan Skvarka, David Michael Johnson, Carrie Brownstein, Ingmar Bruns and Kevin D Bunker.
View institutional ownership trends.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Home Depot (HD), Chevron (CVX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZNTL
• CIK: 1725160
• Web: www.zentalis.com
• Phone: 212-433-3791
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Zentalis Pharmaceuticals: $8.37
• High Price Target: $20.00
• Low Price Target: $2.20
• Potential Upside/Downside: +529.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$165.84 million
• Net Margins: N/A
• Pretax Margin: -245.74%
• Return on Equity: -65.48%
• Return on Assets: -51.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.94
• Quick Ratio: 6.94

Sales & Book Value

• Annual Sales: $67.43 million
• Price / Sales: 1.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.73 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 71,950,000
• Free Float: 70,585,000
• Market Cap: $95.69 million
• Optionable: Optionable
• Beta: 1.59